Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph 790 MG / 9600 UNT) per 4.8 ML Injection
- RxCUI
- 2723772
- RxNorm name
- Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph 790 MG / 9600 UNT) per 4.8 ML Injection
- Display name
- Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph 790 MG / 9600 UNT) per 4.8 ML Injection
- Full name
- Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph 790 MG / 9600 UNT) per 4.8 ML Injection
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:46
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761467 | Keytruda Qlex | pembrolizumab and berahyaluronidase alfa-pmph | 351(a) | Rx | 2026-08-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| KEYTRUDA QLEX | PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH | Merck Sharp & Dohme LLC | 097d166f-b73b-41d3-9b37-7653cd2a0c41 | 2026-07-31 | Warnings, Adverse reactions | 2723772 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 097d166f-b73b-41d3-9b37-7653cd2a0c41 | Keytruda Qlex 790 MG / 9600 UNT in 4.8 ML Injection [PSN] · 4.8 ML berahyaluronidase alfa-pmph 2000 UNT/ML / pembrolizumab-pmph 165 MG/ML Injection [Keytruda Qlex] [SBD] · Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph 790 MG / 9600 UNT) per 4.8 ML Injection [SY] | 3 | 14 | These highlights do not include all the information needed to use KEYTRUDA QLEX safely and effectively. See full prescribing information for KEYTRUDA QLEX. KEYTRUDA QLEX ™ (pembrolizumab and berahyaluronidase alfa-pmph) injection, for subcutaneous use Initial U.S. Approval: 2025 | 20260512 |